Erica R. Sutter

650-335-7626
esutter@fenwick.com
Associate
Litigation

Erica R.
Sutter

Erica R.
Sutter

Erica R.
Sutter

Associate
Litigation

Erica has a passion for learning. Over the course of her career as an antitrust and patent litigator, she has turned this passion into a powerful asset for gaining the detailed knowledge of new technologies and industries necessary to best advocate for her clients. Recent areas of focus in Erica’s practice include pharmaceuticals, medical devices, data analytics, direct-to-consumer retail, telecommunications, and health insurance.

Erica has substantial experience in all phases of trial court litigation, as well as at the appellate level. Her antitrust experience includes representing clients in merger litigation, class action price-fixing litigation, antitrust challenges arising out of settlement agreements from prior pharmaceutical patent cases, and during regulatory agencies’ “second requests.” Her patent litigation experience focuses on pharmaceuticals and involves representing clients both in district court litigation and proceedings before the United States Patent Trial and Appeal Board. Erica also regularly offers her clients strategic counseling on general antitrust and patent considerations. By maintaining an active antitrust and patent practice, Erica is well positioned to help clients navigate the issues that occur at the cross-roads of these two areas of law.

Prior to joining Fenwick, Erica was an associate in the global competition and antitrust group of a leading international law firm. She also previously worked at bio-fabrication startup Modern Meadow. During law school, she was an editor for both the Santa Clara Law Review and the Santa Clara High Technology Journal. As an undergraduate, Erica was involved in research relating to stem cells, including induced pluripotent stem cells, at North Carolina State University College of Veterinary Medicine and at the University College London. More recently, she completed her Master of Animal Science degree at North Carolina State University, where she specifically sought out courses on topics such as metabolism, regulatory affairs of pharmaceutical products, neurobiology, and cancer biology in order to better understand her clients’ industries.

Read more

Antitrust Experience

  • Representation of large music industry company against antitrust claims under both federal and state law. The Court dismissed all claims against the client.
  • Successful defense of convenience store retail analytics company against federal and state antitrust claims—including monopolization, conspiracy to restrain trade, and exclusive dealing allegations—as well as other state law claims pertaining to allegations of unfair competition. Briefed and argued motion to dismiss resulting in dismissal of all claims against client. (19-cv-00455 (D. Conn.)) On appeal, plaintiff ultimately agreed to withdraw its appeal and dismiss all claims against client, with prejudice, prior to any appellate briefing.
  • *Represented one of the nation’s largest health insurers in its defense against the U.S. Department of Justice’s lawsuit to block the then-largest merger ever in the health insurance industry. Erica was a member of the trial team defending the insurance company in the District Court and was also a member of the team representing the company on its expedited appeal to the D.C. Circuit and subsequent petition for writ of certiorari to the U.S. Supreme Court.
  • *Member of team representing a global pharmaceutical company in an antitrust action involving “reverse-payment” claims pertaining to an earlier patent litigation settlement.
  • *Member of team representing a Fortune 100 manufacturer in multidistrict litigation involving alleged price-fixing and output restrictions.

Patent Experience

  • Representation of UCB Inc. and UCB Biopharma Sprl in district court litigation and before the Patent Trial and Appeal Board relating to its patent concerning the drug Xyzal®. UCB successfully obtained a stipulation of infringement in the district court and the later PTAB ruled in favor of UCB on all grounds. Subsequently, Apotex voluntarily dismissed its appeal before the Federal Circuit and stipulated to a permanent injunction in the district court.
  • Representing Novo Nordisk in multiple patent litigations regarding its blockbuster drugs Victoza®, Saxenda® and Ozempic®.
  • Representation of Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation relating to treatment of iron deficiency anemia.

* denotes experience at prior law firm

Antitrust Experience

  • Representation of large music industry company against antitrust claims under both federal and state law. The Court dismissed all claims against the client.
  • Successful defense of convenience store retail analytics company against federal and state antitrust claims—including monopolization, conspiracy to restrain trade, and exclusive dealing allegations—as well as other state law claims pertaining to allegations of unfair competition. Briefed and argued motion to dismiss resulting in dismissal of all claims against client. (19-cv-00455 (D. Conn.)) On appeal, plaintiff ultimately agreed to withdraw its appeal and dismiss all claims against client, with prejudice, prior to any appellate briefing.
  • *Represented one of the nation’s largest health insurers in its defense against the U.S. Department of Justice’s lawsuit to block the then-largest merger ever in the health insurance industry. Erica was a member of the trial team defending the insurance company in the District Court and was also a member of the team representing the company on its expedited appeal to the D.C. Circuit and subsequent petition for writ of certiorari to the U.S. Supreme Court.
  • *Member of team representing a global pharmaceutical company in an antitrust action involving “reverse-payment” claims pertaining to an earlier patent litigation settlement.
  • *Member of team representing a Fortune 100 manufacturer in multidistrict litigation involving alleged price-fixing and output restrictions.

Patent Experience

  • Representation of UCB Inc. and UCB Biopharma Sprl in district court litigation and before the Patent Trial and Appeal Board relating to its patent concerning the drug Xyzal®. UCB successfully obtained a stipulation of infringement in the district court and the later PTAB ruled in favor of UCB on all grounds. Subsequently, Apotex voluntarily dismissed its appeal before the Federal Circuit and stipulated to a permanent injunction in the district court.
  • Representing Novo Nordisk in multiple patent litigations regarding its blockbuster drugs Victoza®, Saxenda® and Ozempic®.
  • Representation of Pharmacosmos A/S and Pharmacosmos Therapeutics in patent litigation relating to treatment of iron deficiency anemia.

* denotes experience at prior law firm

Recognition Recognition Recognition

Recognition Recognition Recognition

Recognition
Patexia

2023

Recognized among the Top ANDA Attorneys

Recognition
Patexia

2023

Recognized among the Top ANDA Attorneys

Login

Don’t have an account yet?

Register